334 replies to this topic

[ImmInst]

Geron Initiates Phase 2 Trial of GRN1005 in Brain Metastases From Breast Cancer
MarketWatch - 3 hours ago

MENLO PARK, Calif., Dec 12, 2011 (BUSINESS WIRE) -- Geron Corporation /quotes/zigman/55630/quotes/nls/gern GERN -3.14% today announced the initiation of GRABM-B (GRN1005 Against Brain Metastases ...

Geron Corporation (GERN) Announces Initiation of Phase 2 Trial of GRN1005 in Brain Metastases From Breast Cancer - StreetInsider.com

View the full article

[ImmInst]

Keeping the Embryonic Stem Cell Hype Alive by Creating a False Impression
First Things - 2 hours ago

This is unbelievable–except it isn't: A front page story in today's SF Chronicle, headlined “Keeping Hope Alive,” purportedly concerns local young woman named Katie Sharify, who was the last ...

View the full article

[ImmInst]

Geron Begins Phase 2 in Breast Cancer Drug Trial
ThirdAge - 1 hour ago

The Geron Corporation announced this week that it plans to enter phase two of its clinical trial testing the drug GRN1005 in patients. According to Medical News Today, the drug treats patients ...

View the full article

[ImmInst]

Geron Initiates Phase 2 Trial of GRN1005 in Brain Metastases From Lung Cancer
MarketWatch - 1 hour ago

Menlo Park, USA, Dec 22, 2011 (Thomson Reuters ONE via COMTEX) -- MENLO PARK, Calif., December 22, 2011 - Geron Corporation /quotes/zigman/55630/quotes/nls/gern GERN -3.52% today announced the ...

View the full article

[ImmInst]

Geron Is Now A Bargain Buy
Seeking Alpha - 2 hours ago

Recently, I was asked my opinion on Geron (GERN) which is a biopharmaceutical company that develops biopharmaceuticals for the treatment of cancer and chronic degenerative diseases. The company ...

View the full article

[platypus]

The stock looks quite bad from a technical point-of-view.

[ImmInst]

Geron to Present at the J.P. Morgan Healthcare Conference
MarketWatch - 5 hours ago

Menlo Park, USA, Jan 05, 2012 (Thomson Reuters ONE via COMTEX) -- MENLO PARK, Calif., January 5, 2012 - Geron Corporation /quotes/zigman/55630/quotes/nls/gern GERN +3.23% today announced that John ...

View the full article

[ImmInst]

Geron Corporation Appoints Graham Cooper as Chief Financial Officer
MarketWatch - 12 hours ago

Menlo Park, USA, Jan 05, 2012 (Thomson Reuters ONE via COMTEX) -- MENLO PARK, Calif., January 5, 2012 - Geron Corporation /quotes/zigman/55630/quotes/nls/gern GERN +4.52% today announced the ...

Geron exec leaves with severance, consulting deal - Bizjournals.com

View the full article

[ImmInst]

Tengion (TNGN) is Making Waves in the Regenerative Medicine Waters: GERN, CYTX
SmallCap Network - 47 minutes ago

By Matthew Briar When investors think of 'regenerative medicine stocks', they tend to think of names like Geron Corporation (NASDAQ:GERN) or Cytori Therapeutics Inc. (NASDAQ:CYTX). So, when little ...

View the full article

[ImmInst]

Geron Completes Enrollment in Phase 2 Clinical Trial of Imetelstat in Breast ...
Reuters - Feb 2, 2012

MENLO PARK, Calif., February 2, 2012 - Geron Corporation (Nasdaq: GERN) today announced that the company has completed enrollment in the randomized Phase 2 clinical trial of imetelstat, in combination with paclitaxel, in patients with locally recurrent ...

View the full article

[ImmInst]

Can Geron Recover in 2012?
DailyFinance - Jan 20, 2012

By Dan Caplinger, The Motley Fool Posted 10:08AM 01/20/12 Investing With 2012 just beginning, now's a great time to gauge how the stocks you're interested in are likely to do this year and beyond.

View the full article

[ImmInst]

Geron Corp: Why I Decided To Take A Flyer On This $2 Biotech Stock
Seeking Alpha - 2 hours ago

Biotech stocks are probably the hardest to get a true handle on unless you have a PHD, a good research staff and more than a little luck.

View the full article

[ImmInst]

Geron Announces Conference Call to Discuss Fourth Quarter and Annual 2011 ...
Reuters - 1 hour ago

Menlo Park, Calif., February 28, 2012 - Geron Corporation (Nasdaq: GERN) will announce its financial results for the fourth quarter and year ended December 31, 2011 on Wednesday, March 7, 2012, after the close of market.

Geron Corp: Why I Decided To Take A Flyer On This $2 Biotech Stock - Seeking Alpha

View the full article

[ImmInst]

Geron Announces Conference Call to Discuss First Quarter 2012 Financial Results
MarketWatch (press release) - 17 minutes ago

Menlo Park, USA, Apr 25, 2012 (Thomson Reuters ONE via COMTEX) -- Menlo Park, Calif., April 25, 2012 - Geron Corporation (NASDAQ:GERN) will announce its financial results for the first quarter ended March 31, 2012 on Wednesday, May 2, 2012, ...

View the full article

[ImmInst]

Geron Completes Enrollment in Phase 2 Clinical Trial of Imetelstat in Non ...
Reuters - 3 hours ago

MENLO PARK, Calif., May 3, 2012 - Geron Corporation (Nasdaq: GERN) today announced that the company has completed planned enrollment of its randomized Phase 2 clinical trial of imetelstat, a telomerase inhibitor, as maintenance therapy following ...

View the full article

[ImmInst]

Geron to Present at the Jefferies 2012 Global Healthcare Conference
Reuters (press release) - Jun 4, 2012

MENLO PARK, Calif., June 4, 2012 - Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, President and Chief Executive Officer, will present an overview of the company at 1:00 pm ET on Wednesday, June 6, at the Jefferies 2012 Global ...

View the full article

[ImmInst]

Equity Briefing: Healthcare Review; ARNA, OSUR and GERN Move
MarketWatch (press release) - 11 hours ago

(Thomson Reuters ONE via COMTEX) -- OraSure Technologies, Inc. (NASDAQ:OSUR) is the biggest gainer after Tuesday's news that its home HIV test was granted by the FDA.

View the full article

[ImmInst]

Stem Cell Revolution: An Interview With Gary Rabin, CEO Of Advanced Cell ...
Seeking Alpha - 1 hour ago

As I have written so many times before, investments in speculative biotech companies are risky endeavors. These companies represent cutting edge technology, and they are the tip of the spear when it comes to our future in healthcare.

View the full article

[ImmInst]

Geron Posts In-Line Loss - Analyst Blog
NASDAQ - 41 minutes ago

Geron Corporation ( GERN ) posted a net loss of 14 cents per share in the second quarter of 2012, in-line with the Zacks Consensus loss Estimate but narrower than the year-ago loss of 17 cents.

Geron Corporation Reports 2012 Second Quarter Financial Results and Events - Reuters

View the full article

[ImmInst]

Research Analysts' Ratings Reiterations for August, 2nd (AGN, ALEX, ALGN ...
Jags Report - 2 hours ago

stock ratings Research Analysts' ratings reiterations for Thursday, August 2nd: Allergan (NYSE: AGN) had its neutral rating reissued by analysts at Zacks.

View the full article

[ImmInst]

Zacks Gives Neutral Rating to Geron (GERN)
Daily Political - 2 hours ago

Geron Co. logo Geron (NASDAQ: GERN)'s stock had its “neutral” rating reiterated by Zacks in a note issued to investors on Thursday.

View the full article

[ImmInst]

Buy Geron: Multiple Catalysts Lie Ahead For This Unique Oncology Company
Seeking Alpha - 1 hour ago

Biotechnology is one of our favorite sectors, because it offers investors the opportunity to invest in companies where the fundamentals truly do matter.

View the full article

[ImmInst]

Geron Gains on Report Touting Experimental Cancer Drugs
Businessweek - 3 hours ago

Geron Corp. (GERN), a Menlo Park, California-based biotechnology company, gained the the most in almost two months after a report on the website Seeking Alpha touted the company's cancer drugs under development.

Buy Geron: Multiple Catalysts Lie Ahead For This Unique Oncology Company - Seeking Alpha

View the full article

[ImmInst]

How Much Longer Can Geron Corp. (NASDAQ: GERN) Survive without Putting a ...
OTCEquity.com - 2 hours ago

Investors who have followed Geron Corp. (NASDAQ: GERN) for any length of time know that the biotechnology company has experienced plenty of highs and lows for the more than two decades they have been in business.

Geron Corp. (GERN) Stock Shoots Up in Thursday's Trading Session - Tech24

View the full article

[ImmInst]

Geron Appoints Andrew Grethlein as Executive Vice President of Technical ...
Reuters - 1 hour ago

MENLO PARK, Calif., September 17, 2012 - Geron Corporation (Nasdaq: GERN) today announced the appointment of Andrew J. Grethlein, Ph.

View the full article

[ImmInst]

Dr. Jean-Paul Castaigne, CEO of Angiochem
FierceBiotech - 13 hours ago

Based: Montreal Founded: 2003. CEO: Dr. Jean-Paul Castaigne Clinical Focus: CNS diseases. Website: www.angiochem.com. The Scoop: The blood-brain barrier poses a major roadblock for ushering drugs from the bloodstream to the central nervous ...

View the full article

[ImmInst]

Zacks Reaffirms Neutral Rating on Geron (GERN)
Jags Report - 2 hours ago

Geron Co. logo Zacks reissued their neutral rating on shares of Geron (NASDAQ: GERN) in a research report released on Thursday morning.

View the full article

[ImmInst]

Geron Appoints Susan Molineaux and Daniel Bradbury to Board of Directors
Reuters - 7 minutes ago

MENLO PARK, Calif., September 28, 2012 - Geron Corporation (Nasdaq: GERN) today announced the appointment of Susan M. Molineaux, Ph.

View the full article

[ImmInst]

Nobel Winner's Stem Cells to Be Tested in Eye Malady in 2013
Businessweek - Oct 8, 2012

Nobel Winner's Stem Cells to Be Tested in Eye Disease Next Year. Thomas Perlmann of Karolinska Institute presents Sir John B. Gurdon of Britain and Shinya Yamanaka of Japan as winners of the 2012 Nobel Prize in medicine or physiology.

View the full article

[ImmInst]

Geron's Last Chance
Seeking Alpha - 1 hour ago

Disclosure: I am long GERN. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha).

View the full article